Adaptation of Human Gut Microbiota to Energetic Restriction (microbaria)

This study is currently recruiting participants.
Verified November 2013 by Assistance Publique - Hôpitaux de Paris
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01454232
First received: October 7, 2011
Last updated: November 13, 2013
Last verified: November 2013

October 7, 2011
November 13, 2013
June 2011
June 2014   (final data collection date for primary outcome measure)
Analyse changes early, medium and long term changes in gut microbiota composition in a kinetic manner [ Time Frame: at 1, 3 and 12 months after surgery ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01454232 on ClinicalTrials.gov Archive Site
  • Establish early, medium and long term changes in insulin sensitivity and GLP1 secretion profile after oral glucose load and look for potential associations between these changes and gut microbiota composition [ Time Frame: 1, 3 and 12 months after surgery ] [ Designated as safety issue: No ]
  • Establish early, medium and long term changes in systemic and adipose tissue inflammation and look for potential associations between gut microbiota composition and inflammation modification [ Time Frame: 1, 3 and 12 months after surgery ] [ Designated as safety issue: No ]
  • Establish early, medium and long term changes in body composition and look for potential associations between these changes and gut microbiota modifications [ Time Frame: 1, 3 and 12 months after surgery ] [ Designated as safety issue: No ]
  • Establish early, medium and long term changes in nutritional blood sample concentrations and look for a potential association between gut microbiota modifications. [ Time Frame: 1, 3, 12 months after surgery ] [ Designated as safety issue: No ]
  • Establish early, medium and long term improvement in obesity related disease (reducing the number of treatments and the need for PPC use) and look for potential association with gut microbiota modification [ Time Frame: 1, 3 and 12 months after surgery ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Adaptation of Human Gut Microbiota to Energetic Restriction
Modification of Human Gut Microbiota in Massive Obesity After Bariatric Surgery: the Role of Energetic Restriction

Gut microbiota ecology is altered in obesity and could link obesity and its complications. Bariatric surgery enables a major and sustained weight loss therefore improving obesity related disease.

the investigators primary aim is to evaluate gut microbiota adaptation to weight loss and the specific role of energetic restriction.

Thus, the investigators plan to compare gut microbiota from 70 obese individuals before and after either restrictive (gastric banding)procedures or gastric bypass procedures.

The prevalence of obesity is rising to an epidemic level. Yet medical and pharmacological treatments have proven their limits. Dietetic modifications contribute to adipose tissue alterations and cross talk dysfunction with other tissues linked to weight maintenance. In a previous study in a model of abrupt weight loss 6 months after Roux-en-Y Bypass, the investigators observed a rapid adaptation of the dominant gut microbiota. Conversely some species were directly linked to the improvement of low grade inflammation independently of calory intake.

Therefore the investigators hypothesized that gut microbiota in obese patients could link food consumption with obesity alterations such as metabolic impairments, energetic storage dysfunction and increased systemic and adipose tissue inflammation.

The investigators want to address the specific role of energetic restriction in gut microbiota modification after weight loss.

To answer that question the investigators will evaluate gut microbiota composition before and during the first year after either gastric banding or gastric bypass surgery.

Our study has several objectives. The investigators also aim to assess whether gut microbiota modification is associated with systemic and tissue inflammation reduction and metabolic improvement during the follow up.

This project is based on a clinical protocol performed in massively obese subjects (BMI>40 kg/m²). The investigators plan to recruit 35 obese patients addressed for gastric banding and 35 candidates for gastric bypass. Clinical phenotype, biochemical analysis, body composition, systemic and adipose tissue inflammation, endotoxemia and gut microbiota will be assessed at baseline and 1, 3 and 12 months after surgery. Specific food consumption will be recorded at every time point.

Associations between all these clinical and biological parameters will be assessed at the different point of the follow up.

More generally, this project might lead us to elucidate a new function of gut microbiota and eventually consider novels anti obesity therapeutic strategies

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
  • Obesity
  • Metabolic Diseases
  • Nutrition Disorders
  • Body Weight
  • Other: stools sampling
    stools sampling at baseline, 3 and 12 months
    Other Name: stools sampling
  • Other: adipose tissue biopsy
    surgical adipose tissue biopsy during surgery, 3 and 12 months
    Other Name: adipose tissue biopsy
gastric surgery
obese patients addressed for gastric surgery
Interventions:
  • Other: stools sampling
  • Other: adipose tissue biopsy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
70
June 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion criteria :

  • Obesity with BMI> 40 kg/m² or obesity with BMI between 35 and 40 kg/M² with comorbidities (OSA, type 2 diabetes, hypertension etc…)
  • Age: 18-60
  • women
  • weight stable for three months preceding surgery

Exclusion criteria :

  • Inflammatory disease
  • Pregnancy
  • Lactose intolerance
  • Antibiotherapy in the three months preceding surgery
  • cancer
  • Drugs (AINS)
Female
18 Years to 60 Years
No
Contact: Karine Clement, MD, PhD 033 1 42 17 70 31 karine.clement@psl.aphp.fr
France
 
NCT01454232
P100111
No
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Not Provided
Principal Investigator: Karine Clement, MD, PhD Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP